HOME >> MEDICINE >> NEWS
Dutch study highlights short-term and long-term options for treatment of tennis elbow

N.B. Please note that if you outside North America the embargo date for Lancet press material is 0001 hours UK time Friday 22 February 2002.

Authors of a study in this weeks issue of THE LANCET conclude that steroid injections offer the best short-term treatment for tennis elbow, with physiotherapy offering marginally better long-term results than a wait-and-see policy.

Tennis elbow (lateral epicondylitis) affects 1-3% of the adult population; symptoms usually last between 6 months and two years, with most patients making a full recovery. The condition is generally treated with corticosteroid injections or physiotherapy. However, Dutch clinical guidelines recommend a wait-and-see policy.

Nynke Smidt and colleagues from Vrije University, Amsterdam, Netherlands, studied patients with tennis elbow of at least 6 weeks duration who were recruited by family doctors. Patients were randomly allocated to 6 weeks of treatment with corticosteroid injections, physiotherapy, or a wait-and-see policy. Outcome measures included general improvement, severity of the main complaint (pain), elbow disability, and patients satisfaction. The severity of elbow complaints, grip strength, and pressure pain threshold were assessed; all outcomes were assessed at 3, 6, 12, 26, and 52 weeks.

185 patients took part in the study. Corticosteroid injections were substantially better than all other therapy options for all outcome measures at 6 weeks; success rates were 92% compared with 47% for physiotherapy and 32% for wait-and-see policy. However, recurrence rate in the injection group was high. Long-term differences between injections and physiotherapy were significantly in favour of physiotherapy; success rates at 52 weeks were 69% for injections, 91% for physiotherapy, and 83% for a wait-and-see policy. However, the better success rate for physiotherapy over a wait-and-see policy was not statistically significant.

Nynke Smidt Comment
'"/>

Contact: Richard Lane
richard.lane@lancet.com
44-0-20-7611-4076
Lancet
21-Feb-2002


Page: 1 2

Related medicine news :

1. Dutch study highlights crying as risk factor for child abuse
2. Controlled study after Dutch caf fire highlights teen mental-health problems after disasters
3. Dutch study links tea drinking to reduced heart attack risk
4. Four researchers awarded Dutch Nobel Prize
5. "Dutch Nobel Prize" for three researchers
6. First head-to-head study to compare lidoderm patch and Celebrex in treating pain
7. UMaine study looks at infants and chronic nighttime crying
8. Chronic pain treatments more effective when taken together, new study shows
9. UNC study: Most N.C. family practitioners engage in unrecognized community service
10. New study in Nature demonstrates protection against cell death during heart attack
11. UCSF study offers insight into human circadian rhythms

Post Your Comments:
(Date:10/22/2014)... Lintelus, Inc., an event software provider, ... Sales, will be speaking on the subject of “Event ... October 28, at the Holiday Inn in New York ... well as a Tech Demo at 12:45pm, to educate ... more engaging event experience. , The Annual Meetings Technology ...
(Date:10/22/2014)... WALTHAM, MA (PRWEB) October 22, 2014 ... developing new solutions for the treatment of bacterial infections, ... J. Sinskey has joined its board of directors. ... Microbiology and Engineering Systems at The Massachusetts Institute of ... the MIT faculty since 1968. Dr. Sinskey also holds ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. ... fertilization (IVF) are only about half as likely as white ... new research indicates, and the racial disparity persists even when ... percent of white patients became pregnant after IVF, compared to ... 4,000 IVF cycles over two years to tease out the ...
(Date:10/22/2014)... By Tara Haelle ... -- Binge drinking among young adult men may lead to ... binge drinking didn,t cause a similar rise in blood pressure ... study. In fact, when young adult women drank lightly or ... half, the study found. "This finding parallels studies in ...
(Date:10/22/2014)... Measures taken by Firestone officials at the company,s ... the spread of the disease there and could prove ... Co. provides health services to about 80,000 employees, retirees, ... Between Aug. 1 and Sept. 23, there were ... people. That incidence rate of 0.09 percent was much ...
Breaking Medicine News(10 mins):Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 4Health News:Tire Company Sets Standard for Ebola Care in Liberia: CDC 2
(Date:10/22/2014)... Provectus Biopharmaceuticals, Inc. (NYSEMKT: PVCT) specializes in ... drug for cancer, is designed for injection into solid ... oncology focus is on melanoma, breast cancer and cancers ... of PV-10 as a therapy for metastatic melanoma, and ... and psoriasis. This summer, the Company ...
(Date:10/20/2014)... Oct. 20, 2014  PneumRx, Inc. ( www.pneumrx.com ), ... announced completion of enrollment in their RENEW Study, nearly ... is the FDA-approved IDE pivotal trial for the PneumRx ... It was anticipated that the study, which began ... take until the end of 2014 to enroll 315 ...
(Date:10/20/2014)... , Oct. 20, 2014 Valeritas, Inc., a ... for patients with Type 2 diabetes, announced today that ... Excellence Award. The award was presented October 16 th ... Columbus, Ohio . The ... across a variety of metrics specifically targeted at the ...
Breaking Medicine Technology:Provectus Biopharmaceuticals Looks at the Asian Markets: Analyst Coverage by Small Cap Traders 2PneumRx Completes RENEW Pivotal Trial Enrollment 2PneumRx Completes RENEW Pivotal Trial Enrollment 3Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 2Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 3
Cached News: